



Date: May 1, 2024

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: New Drug Introduction Report Pursuant to 18 V.S.A. § 4637(c)

To Whom It May Concern:

On April 3, 2024, in pursuant to 18 V.S.A. § 4637(b), United Therapeutics Corporation submitted a new drug introduction notice for the following (the "Product"):

NDC	Product Description	WAC
66302-0716-04	TYVASO DPI Institutional Kit- 16mcg x 16	3,288.57
66302-0732-04	TYVASO DPI Institutional Kit- 32mcg x 16	3,288.57
66302-0748-04	TYVASO DPI Institutional Kit- 48mcg x 16	3,288.57
66302-0764-04	TYVASO DPI Institutional Kit- 64mcg x 16	3,288.57

United Therapeutics Corporation now provides the following additional information pursuant to 18 V.S.A. § 4637(c).

- 1. US and international marketing and pricing plans used at launch:** United Therapeutics Corporation declines to provide this information in accordance with 18 V.S.A. § 4637(d).
- 2. Estimated volume of patients:** This information is confidential and proprietary, and not publicly available or within the public domain.
- 3. Whether the FDA granted breakthrough therapy designation or priority review:** No Breakthrough, Yes Priority review
- 4. Date and price of acquisition:** N/A

United Therapeutics Corporation provides this report consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions.

Thank you for your consideration.

Sincerely,

DocuSigned by:

 4DC49D1B2FA8476...

Felecia Manning